Is there a place for very distal BTK stenting? What are the options for acute PTA failure?
|
|
- Gwendoline Stevens
- 5 years ago
- Views:
Transcription
1 Is there a place for very distal BTK stenting? What are the options for acute PTA failure? Dr. E. Puras Mallagray Hospital Universitario Quirón Madrid SPAIN
2 Faculty disclosure Enrique Puras I disclose the following financial relationships: Consultant for Abbott, Medtronic, Cook, Covidien, Biolitec Employee of CEVIFE Receive grant/research support from Covidien, Urgo, Astra Zeneca Advisory board of Abbott, Angiodynamics
3 BTK approach 2014 Endovascular first Straight line to the foot preferably through dorsalis pedis artery or plantar artery Aggressive angioplasty regardless CTO length Several techniques: Subintimal angioplasty, SAFARY, pedal-distal retrograde punctures Bailout stenting. Spot stenting Angiosome concept
4 BTK lesions Current endovascular strategy BTK for CLI-patients Short focal lesion Long diffuse lesion Calcified/Ostial Bail-out stenting with balloonexp stent PTA Bail-out stenting with self-exp stent PTA with long low-pressure balloons Focal stenting if residual flow-limiting lesion DEDICATED WOUND CARE
5 What should we do if out initial strategy in BTK PTA fails? 1.Unable to cross the lesion.what options do I have? Other GW? Other devices? Retrograde access? 2.Recoil, Dissection.Re- angioplasty? Same ballon or change size?, time? DEB? 3.Rupture, AVF, calcified lesion Stent?, What stent SE or BE?, in what position can we deploy safe? Appropriate technical endpoint for BTK intervention is remained unclear.
6 Unable to cross a lesion: GW Selection Dr M MANZI
7 UNABLE TO CROSS A LESION.
8 Not all crossing tools are created equal, and each has a place in an algorithmic approach to crossing complex CTOs Other devices that CAN help us crossing a BTK lesion: 1. Support catheters: CXI, TRAILBLAZER, Total Across crossing catheters 2. Low profile ballons, hydrophilic, trackability, pushability 3. Mechanical devices. No personal experience The TruePathTM CTO Device (Boston Scientific Corporation) The Phoenix Atherectomy System Peripheral Rotablator Rotational Atherectomy System Diamondback orbital atherectomy system (OAS) (Cardiovascular Systems Inc. [CSI], St. Paul, MN), Natick, MA)
9 Crossing devices can potentially improve procedural outcomes but also come with difficulties. The added cost of these devices can be significant, and some require capital equipment. Thomas P. Davis, MD EVT MAY 2013
10 Failed POBA, Challenges in BTK: Acute complications 1. GUIDEWIRE PERFORATION of the Vessel: - frequent, but not a problem in small vessels - when important / proximal: outside compression with blood pressure cuff - Option nº1 try re-enty and PTA - Option nº 2.retrograde access, trans-collateral
11
12 Retrograde Pedal/tibial access to angioplasty : when to do it. Indications are limited to CLI patients with: Failure of antegrade approach No proximal stump at the origin of the target vessel Immediate origin of collateral at the reinjection-side (danger with antegrade approach to lose the collateral)
13 Pedal access to retrograde tibial angioplasty when to do it. ADVANTAGE DISADVANTAGE IMMEDIATE Already anaesthesia PLANNED Already roadmap Already on the table Good preparation of distal puncture side with doppler and disinfection No preparation of distal puncture side PREP Two times anaesthesia, two times roadmap/ contrast
14 Failed POBA, Challenges in BTK: 2. DISSECTION Acute complications - moderate frequent in vessels below the knee - Option nº 1: prolonged PTA +/-3-5 minutes insufflation time..deb? - Option nº 2: STENT ONLY WHEN FLOW LIMITATION/ Severe Recoil - Spot stenting; Avoid crushing Zones
15 Optimal plain balloon angioplasty Prolonged inflation (180 sec) improves the immediate result of BTK angioplasty compared to short dilation times (30 sec) Significantly fewer major dissections and a modest reduction of residual stenoses are observed N. Zorger et al. Peripheral Arterial Balloon Angioplasty: Effect of Short versus Long Balloon Inflation Times on the Morphologic Results. J Vasc Interv Radiol 2002
16 Current Evidence for DEB in BTK Leipzig Registry (Schmidt A, et al.) Large, singel-center CLI experience DEBATE-BTK (Liistro F, et al.) Small, single-center RCT with 2-year FU InPACT-DEEP (Zeller T, et al.) Large, multi-center, adjudicated (2 core labs) RCT with 1-year follow-up Biolux PII (Brodmann M, et al.) Small, multicenter, RCT bad good
17 Potential Advantage of DEB Ease of use & repeatable Favorable clinical results in fem-pop arteries in reducing restenosis & TLR Local delivery of anti-proliferative drug with nothing leave behind - Less neo-intimal hyperplasia than stents - Stent disadvantaged zones Treat long BTK lesion Preserve future treatment options Cassese S, et al. Circ Cardiovasc Interv. 2012;5(4):582-9
18 Chocolate BAR:
19
20
21 Failed POBA,Challenges in BTK: Acute complications 3. AV-FISTULA - moderate frequent - Option nº1 : prolonged PTA (3-5 min) - STENT ONLY WHEN SEVERE 4. SPASM - Calcium antagonist selective in artery - Papaverine / Nitro μg ia
22
23 BTK DES STENT TRIALS
24 BTK STENTS: ACTUAL PROBLEMS Long BTK segment disease vs currently available short stents Leaving a permanent implant stent induced inflammation, in-stent stenosis and thrombosis Poor runoff into foot stent patency Difficulty in monitoring stent patency COSTS!!!!
25 How distal can we stent a BTK vessel?????? When stenting distally, be sure that: Only stent proximal arteries the distal stent edge is at least 3 cm above the ankle joint to avoid stent injury Stent prone to crush in distal locations due to superficial course of tibial arteries as well as torsional movement It is advisable not to stent across major branches, when the vessel caliber is 2 mm or less, and when the distal runoff below the ankle is poor. Always preserve a distal landing zone (maintain an option for a distal bypass ) 3/4 cm
26 A NEW PARADIGM: VASCULAR REPARATIVE THERAPY BVS Stent Gradual disappearance of supportive structure
27 First experience with BVS in BTK Dr Ramon Varcoe Sydney, Australia LINC Asia-Pacific 18-MAR-2014 Single centre 3 Implanters Chronic lower limb ischemia: RC 3-6 De novo lesions; length 4cm, diameters mm Tibial arteries (distal P3) Sample size: 15 patients
28 Image courtesy Dr Ramon Varcoe
29 Image courtesy Dr Ramon Varcoe
30 RESULTS 10 patients 11 Limbs Age range 73-82yo M:F 60:40 14 Scaffolds Vessels treated ATA ; 2 PTA; 2 PA; 4 TPT; 8 (P3; 0) 100% Technical and Procedural success 1 Acute occlusion (day 1: no DAPT) First experience with BVS in BTK Dr Ramon Varcoe Sydney, Australia LINC Asia-Pacific 18-MAR-2014
31 Challenge in BTK: 5. Acute distal embolization from atherothrombotic debris -Prevention: Carotid Filters -THERAPY: Aspiration Embolectomy Thrombolysis Open Surgical Thrombectomy
32 Take Home message: development of the therapeutic strategy in BTK revascularization Knowledge/EVIDENCE GOOD Materials/TOOLS RESULTS Experience/Patient oriented Indications/LESION TAILORED BAD
33 When bypass is best??!! In cases of Endo-fail (technical, non healing, repeated intervention, mounting cost...) Long, calcified, multi-level disease Large tissue loss Distal target ok Going to live >2 years Those who have good veins. I AM STILL A (endo)surgeon
Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationDisclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview
Tips and Tricks for Tibial Intervention Donald L. Jacobs, MD C Rollins Hanlon Endowed Professor and Chair Chair of Surgery Saint Louis University SSM-STL Saint Louis University Hospital Disclosures Abbott
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationUse of Laser In BTK Disease (CLI)
Use of Laser In BTK Disease (CLI) Click to edit academic affiliation, practice or hospital logo(s) of preference. Product and/or sponsor logos not permitted, per CME guidelines. Richard Kovach, MD, FACC,
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationDisclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
More informationWhen is below-the-ankle angioplasty indicated and how to introduce it into your practice. Roberto Ferraresi. Peripheral Interventional Unit
When is below-the-ankle angioplasty indicated and how to introduce it into your practice Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy www.robertoferraresi.it Disclosure Roberto Ferraresi,
More informationRotarex mechanical thrombectomythe first line option for thrombotic occlusions?
Rotarex mechanical thrombectomythe first line option for thrombotic occlusions? Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant:
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationIn foot treatment : what not to do? clinical experience. E.Ducasse MD PhD FEVBS Unit of vascular surgery CHU bordeaux
In foot treatment : what not to do? clinical experience E.Ducasse MD PhD FEVBS Unit of vascular surgery CHU bordeaux Disclosure Speaker name: Pr E Ducasse I do not have any potential conflict of interest
More informationAccess strategy for chronic total occlusions (CTOs) is crucial
Learn How Access Strategy Impacts Complex CTO Crossing Arthur C. Lee, MD The Cardiac & Vascular Institute, Gainesville, Florida VASCULAR DISEASE MANAGEMENT 2018;15(3):E19-E23. Key words: chronic total
More informationMerits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
More informationCLI Treatment Using Long and Scoring Balloons
CLI Treatment Using Long and Scoring Balloons Robert Beasley, MD Director of Vascular and Interven3onal Radiology Mount Sinai Medical Center Miami Beach, FL Disclosures Consultant/Advisory Board: Abbott
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationAppropriate Device Selection for Endovascular Procedures
Appropriate Device Selection for Endovascular Procedures Thomas M. Shimshak, MD Florida Hospital Heartland Medical Center Sebring, Florida Disclosures Speaker s Bureau: Abbott Vascular Boston Scientific
More informationAtherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
More informationVessel Preparation Prior to DCB and Stenting: How to Do It.
Vessel Preparation Prior to DCB and Stenting: How to Do It. LINC 2018 January 30 February 2, 2018 Leipzig, Germany Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division of Vascular Surgery
More informationDisclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationOrbital Atherectomy. S. Jay Mathews, MD, MS, FACC Interventional Cardiologist, Bradenton Cardiology Center
Orbital Atherectomy S. Jay Mathews, MD, MS, FACC Interventional Cardiologist, Bradenton Cardiology Center Disclosures Clinical Investigator/Research Support Spectranetics, Terumo, Cordis, Abbott Vascular,
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationUC SF. Introduction: Retrograde Access. Pedal Access: When to Do It How Does it Fare. Introduction: Retrograde Access. Introduction: Retrograde Access
Introduction: Retrograde Access Pedal Access: When to Do It How Does it Fare Wide spread application of endovascular techniques to infrageniculate arterial occlusive disease Technical failure rate of crossing
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationSFA lesion treatment: China experience. Wei Liang, MD
SFA lesion treatment: China experience Wei Liang, MD Disclosure I do not have any potential conflict of interest Background PAD: 14% - 20% in adults Aorta & Iliac A: 30% Femoral & Pop A: 80-90% Tibial
More informationDealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?
Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017 Disclosure
More informationEndovascular Options in Critical Limb Ischemia: Below The Knee Therapies
Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies Bret N. Wiechmann, MD FSIR FAHA FSVM Vascular & Interventional Physicians Gainesville, Florida Disclosures Consultant: Medcomp Bard
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationDevice Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015
Disclosure Statement of Financial Interest Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationRationale and algorithm for below-the-knee acute gain optimization
Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it Rationale Restenosis
More informationOlive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan
Olive registry: 3-years outcome of BTK intervention in Japan Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan What is the optimal treatment for the patient with critical limb ischemia (CLI)?
More informationPATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE Disclosure Speaker name: DR. Manar Trab I have the following potential
More informationBTK Case Studies Joseph Cardenas, MD AZ Heart & Vascular, Yuma, AZ
BTK Case Studies Joseph Cardenas, MD AZ Heart & Vascular, Yuma, AZ 1 Case 1 78 yr. old female Rutherford Class II/III lesion 1 block claudicant 2 Pre Treatment Post Treatment Anterior Tibial Artery Occlusion
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationPresent & future of below the knee stenting
Session 5 Below the knee arteries & limb salvage Present & future of below the knee stenting M. Bosiers K. Deloose P. Peeters 1 PRESENT Clinical perspective whom to treat CRITICAL LIMB ISCHEMIA (CLI) 0
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationMechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.
Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips. Dr. Bruno Freitas, Prof., MD Department of Interventional
More informationIntervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI
Intervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI 1 Disclosures I have no financial disclosures related to this talk Objectives 1. Discuss indications for intervention
More informationCalcified lesions optimal treatment
Calcified lesions optimal treatment I give you the latest innovation in balloon angioplasty. Dr. Mathias TISCHLER Hanusch Krankenhaus, Vienna, Austria 1 Nothing to disclose 2 Dienstag, 2. Februar 16 Calcification
More informationWhy and how to prep the vessel
Why and how to prep the vessel Drug elution in the SFA: Leave the right thing behind. Debating evidence to provide an answer Erwin Blessing, MD, FESC SRH Klinikum Karlsbad-Langensteinbach Germany Disclosure
More informationSUPERSUB Trial: 1-yr outcomes of SUPERa SUBintimal stenting in CLI Patients
SUPERSUB Trial: 1-yr outcomes of SUPERa SUBintimal stenting in CLI Patients Dr. L.M. Palena, MD Interventional Radiology Unit Foot & Ankle Clinic Policlinico Abano Terme (PD), ITALY Disclosure I have the
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationNicolas W Shammas, MD, MS
Rota%onal and Aspira%on Atherectomy in Trea%ng in- Stent Restenosis of Femoropopliteal Arteries: Final Results of the JETSTREAM- ISR Feasibility Study Nicolas W Shammas, MD, MS President and Research Director,
More informationCould a combination of DCB + stent be the answer in complex SFA lesions
Could a combination of DCB + stent be the answer in complex SFA lesions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationAtherectomy with thrombectomy of. Rotarex S : The Leipzig experience
Atherectomy with thrombectomy of femoropopliteal occlusions with Rotarex S : The Leipzig experience Dr. Bruno Freitas, Prof., MD Department of Interventional Angiology, Universität Leipzig, Germany Santa
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationWhen and how to use distal protection devices for lower extremity revascularization. Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu
When and how to use distal protection devices for lower extremity revascularization Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu Disclosure Peter A. Schneider Potential conflicts of interest
More informationLUTONIX DCB in BTK Update on the BTK clinical program & single center experience
LUTONIX DCB in BTK Update on the BTK clinical program & single center experience Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclaimer 1. The information
More informationInterventional Radiology in Peripheral Vascular Disease: How Far Can We Go? Dr. L. F. CHENG Department of Radiology Princess Margaret Hospital
Interventional Radiology in Peripheral Vascular Disease: How Far Can We Go? Dr. L. F. CHENG Department of Radiology Princess Margaret Hospital History The era of innovation in image-guided intervention
More information2.4 mm deflecting 2.4 mm tracking Above the knee Phoenix Below the knee 2.2 mm tracking 1.8 mm tracking
Deep femoral artery Superficial femoral artery Popliteal artery Phoenix Above the knee Below the knee Atherectomy system Anterior tibial artery Peroneal artery Posterior tibial artery Dorsalis pedis artery
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationWhat Happened in the IN.PACT Deep Trial. Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL
What Happened in the IN.PACT Deep Trial Zaheed Tai, DO,FACC,FSCAI Bos4ck Heart Center Winter Haven, FL BTK Revasculariza>on Challenges Long, complex, ocen calcified nature of lesions 1 OCen associated
More informationTechnical Aspects for Treating AV Dialysis Fistulae with the IN.PACT DCB. Andrew Holden Auckland Hospital Auckland, New Zealand
Technical Aspects for Treating AV Dialysis Fistulae with the IN.PACT DCB Andrew Holden Auckland Hospital Auckland, New Zealand LINC 2017 26 th January 2017 Disclosure Speaker name: Andrew Holden I have
More informationTHE RETROGRADE APPROACH FOR BELOW-THE- KNEE ANGIOPLASTIES:
THE RETROGRADE APPROACH FOR BELOW-THE- KNEE ANGIOPLASTIES: Massimiliano Fusaro, MD Interventional Cardiologist Hemodynamics and Cardiovascular Interventions Service San Pellegrino Hospital Castiglione
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationWhy and where do I use mechanical debulking for the treatment of arterial occlusions?
Why and where do I use mechanical debulking for the treatment of arterial occlusions? Prof. Thomas Zeller Department Angiology University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany Faculty
More informationKoen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
More informationCalcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease
Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease Thomas M. Shimshak, MD Heart and Vascular Center Florida Hospital Heartland Medical Center
More informationRotarex mechanical debulking: The Leipzig experience in patients
Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Dierk Scheinert
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationAggressive BTK Revascularization and Advanced Wound Care - Patient Specific Therapy Concepts
Aggressive BTK Revascularization and Advanced Wound Care - Patient Specific Therapy Concepts Dr Steven Kum MBBS MMed FRCS FAMS Vascular & Endovascular Surgeon Vascular Centre Department of Surgery Changi
More informationEndovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center
More informationHydrodynamic boost: a novel re-entry technique in distal BTK vessel: when and how to do it
Hydrodynamic boost: a novel re-entry technique in distal BTK vessel: when and how to do it Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy Disclosure Roberto Ferraresi, MD I have the following
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationHow do I use mechanical debulking for the treatment of arterial occlusions
How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationSafety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses
Safety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses Pr Marianne Brodmann, MD Univ. Klinik für Innere Medizin Medizinische Universtität Graz 1 Disclosure
More informationSFA CTO Lesion Management laser or directional atherectomy?
SFA CTO Lesion Management laser or directional atherectomy? Kevin, Chung-Ho Hsu, M.D. Setion of Peripheral Vascular Disease, Division of Cardiology, China Medical University Hospital, Taichung, Taiwan
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationIntravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty
LINC 2015 Global Expert Exchange Forum January 28, 2015 Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty Sahil A. Parikh, M.D. Assistant Professor of Medicine
More informationPHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS PACLITAXEL VS RAPAMYCIN Paclitaxel essentially freezes the microtubules that are in place during cell division. The cells cannot complete cell division
More informationSuperficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
More informationKonstantinos Katsanos, MSc, MD, PhD, EBIR. Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust
Konstantinos Katsanos, MSc, MD, PhD, EBIR Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust King's Health Partners, London, United Kingdom Nothing to declare Anatomy
More informationDISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.
DISRUPT PAD (( Data Summary )) DISRUPT PAD Data Summary SPL 60971 Rev. B 1 Summary of the key findings from the DISRUPT PAD Study 99% of femoropopliteal lesions treated were moderately or severely calcified.
More informationIMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
More informationClinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
More informationAngiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-
Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis- Masahiko Fujihara Kishiwada Tokushukai Hospital, Osaka, Japan Disclosure
More informationEndovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era
Eur Radiol (2014) 24:793 798 DOI 10.1007/s00330-014-3094-0 VASCULAR-INTERVENTIONAL Endovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era Fabrizio Fanelli & Alessandro
More information